Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry
In the study titled, “Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry”, investigators using a worldwide registry explored the efficacy of Immune checkpoint inhibitors (ICIs) in alveolar soft-part sarcoma (ASPS), an ultra-rare sarcoma. ICIs remove the “brakes” put on a patient’s immune system by tumors. Data from adult patients diagnosed with ASPS and treated with ICI (alone or in combination with a drug that blocks certain cell signals) were retrospectively collected and analyzed. Among the 68 assessable patients, there was an overall response rate of 54.4%. After a median follow-up of 36 months, patients had a median progression-free survival (PFS) of 16.3 months. The 12-month and 24-month overall survival (OS) rates were 94% and 81%, respectively. These results suggest that the ICI treatment provides disease control and prolonged OS in patients with advanced ASPS.